← Back to Search

Biguanides

Metformin for Polycystic Ovary Syndrome

N/A
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. Women with PCOS have a high risk of prediabetes, type 2 diabetes and heart disease. The investigators have found a possible change in the DNA (genes of the body that encode all of our traits) that seems to be related to insulin resistance. In this study, the investigators will try to determine whether the change in the gene affects a woman's ability to respond to a common treatment for PCOS, metformin. These studies will uncover the change in a gene that might be one of the causes of PCOS. Discovering this gene will help better understand the diabetes and insulin abnormalities that are common in PCOS and will help us to better diagnose and treat PCOS to prevent the diabetes in these women.

Eligible Conditions
  • Polycystic Ovary Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: MetforminExperimental Treatment2 Interventions
Subjects treated with metformin.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Metformin
FDA approved
Metformin
FDA approved

Find a Location

Who is running the clinical trial?

American Diabetes AssociationOTHER
141 Previous Clinical Trials
99,428 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,521 Total Patients Enrolled
2 Trials studying Polycystic Ovary Syndrome
276 Patients Enrolled for Polycystic Ovary Syndrome
~14 spots leftby Sep 2025